Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Given Consensus Rating of "Hold" by Brokerages

Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Get Free Report) have earned a consensus rating of "Hold" from the fifteen ratings firms that are currently covering the company, Marketbeat Ratings reports. Eight investment analysts have rated the stock with a hold rating and seven have issued a buy rating on the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $35.86.

TNDM has been the topic of a number of research reports. Royal Bank of Canada dropped their price target on Tandem Diabetes Care from $65.00 to $55.00 and set an "outperform" rating on the stock in a research note on Thursday, February 27th. Sanford C. Bernstein downgraded Tandem Diabetes Care from an "outperform" rating to a "market perform" rating and decreased their price objective for the company from $35.00 to $25.00 in a report on Friday, February 28th. Mizuho initiated coverage on shares of Tandem Diabetes Care in a research report on Thursday, April 10th. They set a "neutral" rating and a $20.00 target price on the stock. Morgan Stanley downgraded shares of Tandem Diabetes Care from an "overweight" rating to an "equal weight" rating and reduced their price target for the company from $45.00 to $22.00 in a research report on Wednesday, March 5th. Finally, Stifel Nicolaus decreased their price target on shares of Tandem Diabetes Care from $60.00 to $31.00 and set a "buy" rating for the company in a research note on Thursday, May 1st.

Insider Transactions at Tandem Diabetes Care

In other Tandem Diabetes Care news, COO Jean-Claude Kyrillos bought 10,538 shares of the business's stock in a transaction dated Friday, March 7th. The stock was acquired at an average cost of $18.12 per share, with a total value of $190,948.56. Following the purchase, the chief operating officer now owns 10,538 shares in the company, valued at approximately $190,948.56. This represents a ∞ increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 1.90% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Arizona State Retirement System boosted its position in shares of Tandem Diabetes Care by 1.9% during the 4th quarter. Arizona State Retirement System now owns 18,961 shares of the medical device company's stock worth $683,000 after purchasing an additional 362 shares in the last quarter. Bank of Montreal Can lifted its stake in shares of Tandem Diabetes Care by 4.3% in the fourth quarter. Bank of Montreal Can now owns 10,004 shares of the medical device company's stock valued at $360,000 after purchasing an additional 409 shares during the period. Summit Investment Advisors Inc. lifted its stake in shares of Tandem Diabetes Care by 8.3% in the fourth quarter. Summit Investment Advisors Inc. now owns 6,870 shares of the medical device company's stock valued at $247,000 after purchasing an additional 525 shares during the period. Assetmark Inc. boosted its holdings in Tandem Diabetes Care by 42.9% during the first quarter. Assetmark Inc. now owns 1,750 shares of the medical device company's stock worth $34,000 after buying an additional 525 shares in the last quarter. Finally, AlphaQuest LLC grew its position in Tandem Diabetes Care by 138.7% during the fourth quarter. AlphaQuest LLC now owns 931 shares of the medical device company's stock worth $34,000 after buying an additional 541 shares during the period.

Tandem Diabetes Care Stock Down 6.8%

Shares of NASDAQ:TNDM traded down $1.45 during trading on Friday, hitting $19.83. 1,585,721 shares of the company were exchanged, compared to its average volume of 1,491,498. The firm's 50 day moving average price is $19.44 and its 200-day moving average price is $27.10. Tandem Diabetes Care has a 12-month low of $15.75 and a 12-month high of $53.64. The company has a debt-to-equity ratio of 1.29, a current ratio of 2.90 and a quick ratio of 2.32. The stock has a market capitalization of $1.32 billion, a P/E ratio of -10.27 and a beta of 1.47.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last announced its quarterly earnings results on Wednesday, April 30th. The medical device company reported ($0.67) earnings per share for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.07). The company had revenue of $234.42 million during the quarter, compared to analysts' expectations of $220.19 million. Tandem Diabetes Care had a negative net margin of 14.84% and a negative return on equity of 44.19%. Tandem Diabetes Care's revenue was up 22.3% on a year-over-year basis. During the same period last year, the firm earned ($0.65) earnings per share. On average, research analysts predict that Tandem Diabetes Care will post -1.68 earnings per share for the current fiscal year.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.